Brentuximab vedotin (1.8 mg/kg intravenously every 3 weeks) was subsequently evaluated in a pivotal phase 2 study of 102 patients with relapsed/refractory CD30+ HL after auto-SCT [49]. The gene discussed is TNFRSF8; the disease is Hodgkins lymphoma.